ORIGINAL RESEARCH article
Front. Immunol.
Sec. Antigen Presenting Cell Biology
MGAT1 knockout in human dendritic cells enhance CD8+ T cell activation
Provisionally accepted- 1DTU Bioengineering, Lyngby, Denmark
- 2Technical University of Denmark, Kongens Lyngby, Denmark
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Dendritic cells (DCs) are crucial in regulating immune responses, making them a compelling target for immunotherapy. While DC vaccines have demonstrated safety and feasibility, their limited clinical efficacy underscores the need for strategies to enhance DC functionality. Emerging evidence highlights the regulatory roles of sialoglycans in DC biology, yet the structure-function relationships of other glycans remain poorly understood. To aid the understanding of DC glycobiology, we recently developed and validated a human model system based on genetically glycoengineered MUTZ-3-derived DCs and showed that ST6GAL1-mediated α2,6-sialylation specifically modulates CD4⁺ T cell activation. In this study, we knocked-out (KO) mannosyl (α-1,3-)-glycoprotein β-1,2-N-acetylglucosaminyltransferase (MGAT1) to investigate how the shift from complex to oligomannose N-glycans affects DC biology and function. MGAT1 KO completely abolished the synthesis of complex and hybrid N-glycans. Differentiation of MGAT1 KO MUTZ-3 cells into immature DCs (iDCs) induced upregulation of DC markers including CD1a, CD80, CD86, CCR6, and CD209, comparable to the upregulation observed in WT iDCs. Interestingly, MGAT1 KO iDCs displayed an 2 This is a provisional file, not the final typeset article enhanced immunostimulatory profile, marked by increased surface densities of CD40, HLA-ABC, and HLA-DR, in combination with elevated mRNA levels of NFKB1 and IFNB1. Consistent with this profile, MGAT1 KO iDCs highly enhanced the activation and proliferation of allogeneic human CD8+ T cells in vitro, resulting in significantly higher levels of secreted proinflammatory cytokines compared to WT iDCs. This enhanced CD8⁺ T cell activation persisted under PD-L1 blockade, underscoring the robustness of the MGAT1 KO–driven effect. Significantly elevated NFKB1 levels in the MGAT1 KO iDCs suggest enhanced NF-κB activity driving HLA and costimulatory molecule upregulation and robust CD8+ T cell activation. We further demonstrate that MGAT1 KO promotes accelerated DC differentiation, yielding DCs that after three days of differentiation acquire the capacity to activate T cells. Building on previous research into sialic acids in DC biology, our findings reveal a regulatory role for complex and hybrid N-glycans and specifically demonstrate how sialic acids on N-glycans influence distinct functional outcomes in T cell activation. Our findings support cell-based glycoengineering as an effective strategy to improve DC-based immunotherapies.
Keywords: CD8+ T cell response, CRISPR/Cas9, DC differentiation, dendric cells (DCs), N-glycosylation
Received: 06 Mar 2025; Accepted: 03 Dec 2025.
Copyright: © 2025 Blomberg, Henriksen, Tian, Skovgaard, Skovbakke and Goletz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Steffen Goletz
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
